Travere Therapeutics, Inc. announced that its chief medical officer, Noah Rosenberg, M.D., would be transitioning to an executive advisor role effective January 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.72 USD | +4.04% | +25.32% | -14.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.13% | 588M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.25% | 22.48B | |
-9.65% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- TVTX Stock
- News Travere Therapeutics, Inc.
- Travere Therapeutics, Inc. Announces Executive Changes